A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants
- Resource Type
- Article
- Source
- In
Contemporary Clinical Trials Communications December 2023 36 - Subject
- Language
- ISSN
- 2451-8654